Multiple coronary stenting in unstable angina: Early and late clinical outcomes

Chauhan, Anoop; Vu, Erik; Ricci, Donald R.; Buller, Christopher E.; Moscovich, Michael D.; Monkman, Stephanie; Penn, I

doi:10.1002/(sici)1097-0304(199801)43:1<11::aid-ccd4>3.0.co;2-b

Cited by 7 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 And although balloon angioplasty and stenting have significant risks of myocardial infarction or vessel stenosis/thrombosis (approximately 5% each), as well as need for CABG surgery (3–8%), the risk of stroke is much less than for CABG: 0.4–0.8% in some series, and 0% in others. 14–16 Cognitive deficits not accompanied by frank stroke following balloon angioplasty and/or stenting are rare (in contrast to CABG surgery), since they are not customarily noted. Presumably the decreased risk of stroke in interventional procedures for coronary artery stenosis‐in comparison with CABG surgery‐is due to the lack of microemboli showering into the cerebral circulation.…”

Section: An Example Of Progress In Intraoperative Neuroprotectionmentioning

confidence: 99%

Neuroprotective “Agents” in Surgery: Secret “Agent” Man, or Common “Agent” Machine?

Andrews

1999

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The search for clinically-effective neuroprotective agents has received enormous support in recent years--an estimated $200 million by pharmaceutical companies on clinical trials for traumatic brain injury alone. At the same time, the pathophysiology of brain injury has proved increasingly complex, rendering the likelihood of a single agent "magic bullet" even more remote. On the other hand, great progress continues with technology that makes surgery less invasive and less risky. One example is the application of endovascular techniques to treat coronary artery stenosis, where both the invasiveness of sternotomy and the significant neurological complication rate (due to microemboli showering the cerebral vasculature) can be eliminated. In this paper we review aspects of intraoperative neuroprotection both present and future. Explanations for the slow progress on pharmacologic neuroprotection during surgery are presented. Examples of technical advances that have had great impact on neuroprotection during surgery are given both from coronary artery stenosis surgery and from surgery for Parkinson's disease. To date, the progress in neuroprotection resulting from such technical advances is an order of magnitude greater than that resulting from pharmacologic agents used during surgery. The progress over the last 20 years in guidance during surgery (CT and MRI image-guidance) and in surgical access (endoscopic and endovascular techniques) will soon be complemented by advances in our ability to evaluate biological tissue intraoperatively in real-time. As an example of such technology, the NASA Smart Probe project is considered. In the long run (i.e., in 10 years or more), pharmacologic "agents" aimed at the complex pathophysiology of nervous system injury in man will be the key to true intraoperative neuroprotection. In the near term, however, it is more likely that mundane "agents" based on computers, microsensors, and microeffectors will be the major impetus to improved intraoperative neuroprotection.

show abstract

Section: An Example Of Progress In Intraoperative Neuroprotectionmentioning

confidence: 99%

Neuroprotective “Agents” in Surgery: Secret “Agent” Man, or Common “Agent” Machine?

Andrews

1999

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

Intracoronary stenting: Where we are, where are we going?

Nobuyoshi

Kimura

1998

Cathet. Cardiovasc. Diagn.

View full text Add to dashboard Cite

Initial results of the quanam drug eluting stent (QuaDS‐QP‐2) registry (BARDDS) in human subjects

Fuente

Miano²,

Mrad³

et al. 2001

Cathet Cardio Intervent

View full text Add to dashboard Cite

Thirty-two patients presenting with varied coronary syndromes and anatomy were treated with a new coronary multisleeve drug delivery coronary stent (QuaDS-QP-2) containing up to 4,000 microg of a taxol-derived lipophilic microtubule inhibitor (QP2). The device was successfully implanted in 32 patients who have been followed for up to 2 years. Twenty-five patients have undergone stress ECHO or SPECT Thallium and all are currently asymptomatic. Thirteen patients have already been restudied angiographically, by IVUS and/or by SPECT Thallium testing and are detailed in this report. Angiographic, IVUS, and SPECT Thallium have been controlled at a mean of 11.2 months (range, 6-15 months) in this 13-patient cohort. Although all 13 QuaDS-QP-2 (QDES) stents were angiographically and IVUS patent, two reinterventions have been required in the 32-patient study group thus far, both relate to either new disease or to distal, small-vessel disease beyond the stent. There was no evidence of significant proliferation in the QDES devices. On the basis of this preliminary data and a European pilot study, a controlled randomized trial (SCORE) is currently in progress in western Europe.

show abstract

Multiple coronary stenting in unstable angina: Early and late clinical outcomes

Cited by 7 publications

References 34 publications

Neuroprotective “Agents” in Surgery: Secret “Agent” Man, or Common “Agent” Machine?

Neuroprotective “Agents” in Surgery: Secret “Agent” Man, or Common “Agent” Machine?

Intracoronary stenting: Where we are, where are we going?

Initial results of the quanam drug eluting stent (QuaDS‐QP‐2) registry (BARDDS) in human subjects

Contact Info

Product

Resources

About